Cellogen Therapeutics raises $2 million funding from Kotak Alts

The company will use this funding to develop its CAR-T cancer treatment programs and expand its gene therapy research projects.

It will also upgrade its manufacturing setup and strengthen regulatory systems to meet GMP (Good Manufacturing Practice) standards for safe and high-quality production.

Ashish Ranjan, Director at Kotak Alts, said, “India carries a high burden of blood cancers and genetic blood disorders, yet access to advanced therapies such as CAR‑T and gene therapy remains limited, largely due to cost. Cellogen is working to address this gap through an indigenous, IP‑led platform that brings together next‑generation science and cost‑efficient development. Its bispecific CAR‑T programme places the company among a small group working on advanced multi targeted CAR‑T approaches globally. We see the potential for meaningful clinical impact and for building scalable, affordable cell and gene therapy capabilities from India.”

Dr. Gaurav Kharya, Co‑Founder, Cellogen Therapeutics, said, “Cell and gene therapies have the potential to fundamentally change how many diseases are treated. However, challenges around cost, scalability, and access continue to limit their adoption. With the support of partners like NATCO and Kotak Alts, we are focused on building therapies that are innovative, cost‑effective, and practical to scale for wider patient access.”

Dr. Tanveer Ahmad, Co‑Founder, Cellogen Therapeutics, added, “Our AI‑driven platforms are central to how we design and develop cell and gene therapies. This partnership gives us the opportunity to scale these efforts and move more decisively toward next‑generation approaches, including in vivo CAR‑T therapies.”

Founded in 2021 by Dr. Gaurav Kharya and Dr. Tanveer Ahmad, Cellogen Therapeutics is a Delhi-based biotech startup that works on cell and gene therapy to develop advanced CAR-T treatments for cancer and blood-related diseases. Its aim is to make these life-saving treatments more affordable and accessible.

The company is building a special CAR-T therapy that targets two cancer markers instead of just one. This dual-target approach may make treatment more effective and can also help lower the chances of cancer coming back compared to traditional CAR-T methods.

Cellogen is preparing for its first human clinical trials (Phase I) with regulatory approval, in partnership with Christian Medical College, Vellore. It also received a patent last year for its CAR-T technology platform.

Along with cancer research, the startup is also working on early treatments for diseases like beta thalassemia and sickle cell disease. Earlier, Natco Pharma invested in the company by buying more than a 5% stake for ₹15 crore.

Read More- Trackk raises $3.16 million in seed round led by Lightspeed